Get started

PHARMA

Newest Alert is $CBIO$CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million. Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months. Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017 Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows: Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS) Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments: Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor Anticipated Milestones CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017
CLong
by StockGuild
Lupin is a Good Buy at current levels!Lupin is one of the top Pharma companies with an excellent Balance Sheet, Sales Revenue growth and a very good future. From long term investment point of view, this is an excellent company to have in your portfolio and current levels of 1250 are an excellent entry. One can add more if it dips further as this stock itself promises to give 20% + returns within or much before an year.. Technically.. Weekly charts shows Fibonacci retracements to 50% and good chances of a bounce from here very soon...
NSE:LUPINLong
by traderparag
$1.25 Price target (65k shares)2017 price target is $1.25, analysis shows me we should reach 1.25 or higher in the next 12 months. I had to sell $RNVA for +10% here as this play is too good to pass up. Company is EXTREMELY undervalued given the things in the work for 2017. Several patents, topical Viagra in the works, entrance into the Medical Marijuana sector...Company should also fair well and benefit from the repeal of Obamacare. This will be one to watch, lock in profits don't get emotional. Good money to be made long term.
OTC:VDRMLong
by Cryptocol